SN. Stock Overview
Develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
Smith & Nephew plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£9.75 |
52 Week High | UK£12.45 |
52 Week Low | UK£9.11 |
Beta | 0.70 |
11 Month Change | -13.43% |
3 Month Change | -16.68% |
1 Year Change | -5.54% |
33 Year Change | -22.82% |
5 Year Change | -44.47% |
Change since IPO | 4,818.07% |
Recent News & Updates
Recent updates
Investors Still Waiting For A Pull Back In Smith & Nephew plc (LON:SN.)
Oct 31Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital
Sep 25Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are
Aug 08Smith & Nephew (LON:SN.) Will Be Hoping To Turn Its Returns On Capital Around
Jun 16Smith & Nephew plc (LON:SN.) Not Flying Under The Radar
Apr 16Is Smith & Nephew plc (LON:SN.) Trading At A 30% Discount?
Mar 16Capital Allocation Trends At Smith & Nephew (LON:SN.) Aren't Ideal
Feb 21Is Smith & Nephew plc (LON:SN.) Trading At A 36% Discount?
Dec 15Is Smith & Nephew (LON:SN.) Using Too Much Debt?
Nov 30Smith & Nephew (LON:SN.) Could Be Struggling To Allocate Capital
Oct 29Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price
Sep 11Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet
Aug 19Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital
Jul 17Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate
Jun 11Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly
May 09Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends
Apr 09Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)
Feb 09We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt
Nov 21Returns On Capital Signal Tricky Times Ahead For Smith & Nephew (LON:SN.)
Nov 08Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 99% Above Its Share Price
Oct 26These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Reasonably Well
Aug 11There Are Reasons To Feel Uneasy About Smith & Nephew's (LON:SN.) Returns On Capital
Jul 28Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 58% Above Its Share Price
Jun 26Shareholder Returns
SN. | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | 2.5% | -1.5% | 1.0% |
1Y | -5.5% | -1.1% | 6.3% |
Return vs Industry: SN. underperformed the UK Medical Equipment industry which returned -1.1% over the past year.
Return vs Market: SN. underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
SN. volatility | |
---|---|
SN. Average Weekly Movement | 4.4% |
Medical Equipment Industry Average Movement | 6.0% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 10.2% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SN. has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: SN.'s weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1856 | 18,000 | Deepak Nath | www.smith-nephew.com |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Smith & Nephew plc Fundamentals Summary
SN. fundamental statistics | |
---|---|
Market cap | UK£8.50b |
Earnings (TTM) | UK£241.17m |
Revenue (TTM) | UK£4.46b |
35.2x
P/E Ratio1.9x
P/S RatioIs SN. overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SN. income statement (TTM) | |
---|---|
Revenue | US$5.64b |
Cost of Revenue | US$1.67b |
Gross Profit | US$3.97b |
Other Expenses | US$3.66b |
Earnings | US$305.00m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
Feb 25, 2025
Earnings per share (EPS) | 0.35 |
Gross Margin | 70.33% |
Net Profit Margin | 5.41% |
Debt/Equity Ratio | 66.7% |
How did SN. perform over the long term?
See historical performance and comparison